A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
← catalyst calendarSponsored by Krystal Biotech, Inc. (industry) · KRYS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
85actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-07 | actual | When the study began enrolling |
| Primary completion | 2024-10-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-09-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Skin Roughness
- Wrinkle
- Fine Lines
- Skin Thickness
Interventions
- Biological: KB301
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAssessment of the safety profile of KB301 by recording adverse events using MedDRA System Organ Class and Preferred Term and collection of other clinical study procedures.
measured 4 months
Permalink · KRYS's whole pipeline · Catalyst calendar · Every registered study · What changed